Type 1 Diabetes Clinical Trial
— SMARTOfficial title:
Optimising Glycaemia Around Dynamic Physical Exercise With Advanced Hybrid-closed-loop Therapy Use in Type 1 Diabetes: ''The SMART Study''
Verified date | October 2022 |
Source | Steno Diabetes Center Copenhagen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Despite the promising data emanating from trials investigating the effectiveness of advanced hybrid closed loop (AHCL) insulin delivery systems in managing glycaemia in those with type 1 diabetes (T1D), we currently know little about their efficacy in optimising glycaemia when physical activity is factored into the equation. With the introduction of new AHCL systems that have novel technological features, we are left with important questions of how to optimise their use around physical exercise to not only minimise dysglycaemia, but also encourage individuals with T1D to lead a physically active lifestyle for the associated wider health benefits. This will be a three-period, randomised, cross-over study with a single-hormone (insulin) AHCL system that compares the efficacy of three insulin management strategies: (i) unannounced exercise and a full dose of meal-time insulin 90-minutes prior to commencement, (ii) a 25% reduced dose of meal-time insulin with exercise announcement 90-minutes prior to commencement and (iii) a 25% dose reduction in meal-time insulin with exercise announcement 45-minutes prior to commencement, in optimising TIR around dynamic physical exercise in adults with T1D.
Status | Completed |
Enrollment | 10 |
Est. completion date | August 23, 2022 |
Est. primary completion date | August 23, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - • Type 1 diabetes =2 years. - HbA1c; - 58-63 mmol/mol (maximum 30% of participants) OR - = 64 mmol/mol (minimum 70% of participants) - Insulin pump treatment =12 months - CGM or isCGM use =6 months - Novorapid use =4 weeks - Carbohydrate counting and use of the insulin pump bolus calculator for most snacks and meals. - Carbohydrate intake >80 grams per day (assessed by review of intake recorded in the insulin pump during the 2 weeks prior to the screening visit) Exclusion Criteria: - • Breast-feeding, pregnancy or planning to become pregnant. - Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start. - Use of hybrid closed-loop systems - Daily use of paracetamol (acetaminophen) - Alcohol or drug abuse. - Severe cardiac disease or retinopathy contraindicating HbA1c <53 mmol/mol. - Other concomitant medical or psychological condition that according to the investigator's assessment makes the person unsuitable for study participation. - Lack of compliance with key study procedures at the discretion of the investigator. - Unacceptable adverse events at the discretion of the investigator. |
Country | Name | City | State |
---|---|---|---|
Denmark | Steno Diabetes Center Copenhagen | Gentofte |
Lead Sponsor | Collaborator |
---|---|
Steno Diabetes Center Copenhagen | Swansea University |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Comparison of the occurrence of BG hypoglycaemic events | Comparison of the occurrence of blood glucose hypoglycaemic events before during and 1 hour after exercise | -90 min to +105 min | |
Other | Comparison of the depth of BG hypoglycaemic events | Comparison of the depth of blood glucose hypoglycaemic events before during and 1 hour after exercise | -90 min to +105 min | |
Other | Comparison of mean BG concentrations | Comparison of mean blood glucose concentrations before during and 1 hour after exercise | -90 min to +105 min | |
Other | Comparison of the standard deviation in BG concentrations | Comparison of the standard deviation in blood glucose concentrations before during and 1 hour after exercise | -90 min to +105 min | |
Other | Comparison of the coefficient of variation in BG concentrations | Comparison of the coefficient of variation in blood glucose concentrations before during and 1 hour after exercise | -90 min to +105min | |
Other | Comparison of the minimum BG concentration | Comparison of the minimum blood glucose concentration before during and 1 hour after exercise | -90 min to +105min | |
Other | Comparison of the maximum BG concentration | Comparison of the maximum blood glucose concentration before during and 1 hour after exercise | -90 min to +105min | |
Other | ?BGexercise: Changes in BG concentrations during exercise | ?BGexercise: Changes in blood glucose concentrations during exercise | 0 min to +45 min | |
Other | ?iGexercise: Changes in iG concentrations during exercise | ?iGexercise: Changes in interstitial glucose concentrations during exercise | 0 min to +45 min | |
Other | ?BGfeeding: Change in BG concentrations after feeding | ?BGfeeding: Change in blood glucose concentrations after feeding | -90 min to 0min | |
Other | ?iGfeeding: Change in iG concentrations after feeding | ?iGfeeding: Change in interstitial glucose concentrations after feeding | -90 min to 0min | |
Other | Comparison of TBR level 2 in iG values | Comparison of TBR level 2 in interstitial glucose values before during and 1 hour after exercise | -90 min to +105 min | |
Other | Comparison of TBR level 1 in iG values | Comparison of TBR level 1 in interstitial glucose values before during and 1 hour after exercise | -90 min to +105 min | |
Other | Comparison of TAR level 1 in iG values | Comparison of the amount of time spent with interstitial glucose values above the target range level 1 before during and 1 hour after exercise | -90 min to +105 min | |
Other | Comparison of TAR level 2 in iG values | Comparison of the amount of time spent with interstitial glucose values above the target range level 2 before during and 1 hour after exercise | -90 min to +105 min | |
Other | Comparison of mean iG concentrations | Comparison of mean interstitial glucose concentrations before during and 1 hour after exercise | -90 min to +105 min | |
Other | Comparison of the standard deviation in iG concentrations | Comparison of the standard deviation in interstitial glucose concentrations before during and 1 hour after exercise | -90 min to +105 min | |
Other | Comparison of the coefficient of variation in iG concentrations | Comparison of the coefficient of variation in interstitial glucose concentrations before during and 1 hour after exercise | -90 min to +105 min | |
Other | Comparison of the minimum iG concentration | Comparison of the minimum interstitial glucose concentration before during and 1 hour after exercise | -90 min to +105 min | |
Other | Comparison of the maximum iG concentration | Comparison of the maximum interstitial glucose concentration before during and 1 hour after exercise | -90 min to +105 min | |
Primary | Comparison of TIR in blood glucose values during, and 1-hour after, dynamic physical exercise. | To compare the amount of time spent with blood glucose values within the target range during, and 1-hour after, dynamic physical exercise | -90 min to +105 min |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|
||
Completed |
NCT02855307 -
Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes
|
Phase 2 |